David vilanova

🧬 In-Vivo CAR-T: Pharma’s New Holy Grail Ex-vivo cell therapy was biotech’s moonshot. But it’s running into gravity, manufacturing drag, cost friction, and clinical complexity. The next frontier is in-vivo CAR-T, programming immune cells directly inside the body. Pharma’s deal flow makes the shift obvious. > $ABBV bought Capstan for its targeted LNPs. > $GILD took Interius for integrating in-vivo delivery. >$AZN scooped EsoBiotec for immune-tropic vectors > $BMY grabbed Orbital for circular RNA payloads. These aren’t bets on “CAR-T 2.0.” They’re bets on skipping the cell therapy factory. ⚙️ What Pharma is Buying 1️⃣ Delivery that actually hits T cells. Platforms with immune-tropic vectors or LNPs that deliver RNA/DNA directly to lymphocytes are the crown jewels. The focus is on delivery/tropism and human data proving transduction at drug-like doses. 2️⃣ Autoimmune first, oncology second. Autoimmune diseases are the new on-ramp. Rebooting B-cells with in-vivo CD19 or CD20 CARs offers a faster regulatory path and cleaner biomarkers than solid tumors. 3️⃣ Control layers. Investors miss this: buyers aren’t paying for “permanent cures.” They’re paying for reversible control. RNA or epigenetic switches that let you turn therapy off, re-dose, and manage risk are where the value pools sit. 4️⃣ CMC scalability. If a CAR-T can be shipped like Humira, not manufactured like a transplant, it’s a platform. Simple fill-finish beats elegant biology every time. 💡 What Differentiation Looks Like >Immune reset, not immune destruction. Design for measurable immune recalibration (e.g., B-cell depletion, autoantibody drop, reconstitution window) with built-in rescue drugs. It’s a narrative payers understand. >Targeted LNP + circRNA stack. CircRNA extends expression without permanent edits, and LNP tropism turns dosing into a controllable dial. It’s the combination investors should hunt for. >Non-genotoxic engineering. Replace DNA cuts with transient RNA knockdowns (Cas13) or epigenetic silencing. Same function, lower risk, and better suited for systemic delivery. > Programmability over potency. Logic-gated CARs that activate only in certain cytokine or antigen contexts will dominate next-gen designs. Think conditional biology, not brute force. 🧭 What Comes Next >The endgame is obvious: off-the-shelf in-vivo immunomodulation that looks like a biologic and behaves like gene therapy. >First applications will be autoimmune reset, then solid tumor infiltration, then regenerative immune programming. >Pharma’s M&A tells you where translation is headed, away from autologous complexity and toward drug-like cell engineering. cell.com/trends/cancer/fullt…